Dr.Tannock obtained his PhD in London, England for studies of cell population kinetics. After postdoctoral studies at MD Anderson Hospital, he studied medicine at University of Pennsylvania. He completed training as a Medical Oncologist at Princess Margaret Hospital in 1978, and apart from a sabbatical year in France has remained there as a clinician/scientist.
Dr. Tannock’s clinical research has investigated methodological issues related to cancer clinical trials, with emphasis on endpoints of clinical benefit. He chaired randomized clinical trials for men with metastatic prostate cancer that led to licensing of current chemotherapy. His laboratory-based research evaluates effects of the solid tumour microenvironment on outcome of cancer therapy.
Dr Tannock was a member of the ASCO Board of Directors. He has received the M.D. Anderson Outstanding Alumnus award and the Warwick Prize from the National Cancer Institute of Canada, for research that impacted on cancer control. He received an honorary DSc degree from London University, UK in 2009. He chairs the scientific audit committee of the EORTC